Index S&P 500
P/E 29.04
EPS (ttm) 3.81
Insider Own 0.36%
Shs Outstand 295.26M
Perf Week -1.41%
Market Cap 32.40B
Forward P/E 19.33
EPS next Y 5.73
Insider Trans -0.42%
Shs Float 291.54M
Perf Month -7.48%
Income 1.13B
PEG 3.65
EPS next Q 1.35
Inst Own 91.17%
Short Float / Ratio 1.39% / 2.10
Perf Quarter -5.39%
Sales 6.99B
P/S 4.63
EPS this Y 3.83%
Inst Trans -3.34%
Short Interest 4.04M
Perf Half Y -16.79%
Book/sh 18.99
P/B 5.83
EPS next Y 5.68%
ROA 10.71%
Target Price 139.41
Perf Year -10.33%
Cash/sh 4.54
P/C 24.38
EPS next 5Y 7.95%
ROE 21.28%
52W Range 109.00 - 160.26
Perf YTD -26.01%
Dividend 0.90
P/FCF 22.82
EPS past 5Y 14.76%
ROI 13.66%
52W High -30.91%
Beta 1.04
Dividend % 0.81%
Quick Ratio 1.68
Sales past 5Y 9.02%
Gross Margin 53.82%
52W Low 1.59%
ATR 2.77
Employees 18100
Current Ratio 2.29
Sales Q/Q -2.68%
Oper. Margin 23.49%
RSI (14) 34.91
Volatility 1.84% 2.40%
Optionable Yes
Debt/Eq 0.50
EPS Q/Q -65.80%
Profit Margin 16.20%
Rel Volume 0.72
Prev Close 111.94
Shortable Yes
LT Debt/Eq 0.49
Earnings Aug 15 AMC
Payout 20.10%
Avg Volume 1.92M
Price 110.73
Recom 1.95
SMA20 -4.34%
SMA50 -8.23%
SMA200 -16.87%
Volume 1,392,358
Change -1.08%
Date
Action
Analyst
Rating Change
Price Target Change
Jul-31-23 Downgrade
Evercore ISI
Outperform → In-line
$126 → $124
May-24-23 Reiterated
Wells Fargo
Overweight
$170 → $160
May-24-23 Reiterated
TD Cowen
Outperform
$168 → $145
May-24-23 Reiterated
SVB Securities
Outperform
$170 → $145
May-24-23 Reiterated
Stifel
Hold
$153 → $135
May-24-23 Reiterated
Robert W. Baird
Outperform
$174 → $144
May-24-23 Reiterated
Evercore ISI
Outperform
$150 → $126
May-24-23 Reiterated
Credit Suisse
Outperform
$170 → $160
May-24-23 Reiterated
Citigroup
Neutral
$150 → $130
May-24-23 Reiterated
BofA Securities
Buy
$164 → $144
May-24-23 Reiterated
Barclays
Equal Weight
$140 → $135
May-24-23 Downgrade
KeyBanc Capital Markets
Overweight → Sector Weight
May-11-23 Initiated
Barclays
Equal Weight
$140
Jan-10-23 Upgrade
Wells Fargo
Equal Weight → Overweight
$170
Aug-25-22 Initiated
Credit Suisse
Outperform
$165
Jul-20-22 Initiated
UBS
Buy
$139
Jul-08-22 Downgrade
Citigroup
Buy → Neutral
$175 → $140
Apr-25-22 Downgrade
Wells Fargo
Overweight → Equal Weight
$130
Feb-23-22 Reiterated
Wells Fargo
Overweight
$180 → $160
Feb-23-22 Reiterated
Stifel
Hold
$169 → $145
Show Previous Ratings
Sep-20-23 03:06PM
01:13PM
10:15AM
Sep-18-23 09:00PM
01:03PM
01:11PM
Loading…
Sep-15-23 01:11PM
Sep-14-23 11:30AM
Sep-12-23 08:35AM
Sep-05-23 10:36AM
07:45AM
07:40AM
07:35AM
07:20AM
05:34AM
Sep-01-23 08:34AM
08:00AM
Loading…
Aug-24-23 08:00AM
Aug-21-23 04:26PM
10:49AM
Aug-17-23 11:38AM
Aug-16-23 05:07PM
01:48PM
12:59PM
12:37PM
07:55AM
(Thomson Reuters StreetEvents)
Aug-15-23 08:04PM
06:31PM
06:27PM
06:00PM
04:15PM
04:05PM
02:00PM
Loading…
Aug-13-23 02:00PM
Aug-11-23 11:56AM
Aug-09-23 06:15PM
08:00AM
Aug-03-23 08:00AM
07:25AM
Aug-02-23 03:32PM
Jul-31-23 04:26PM
(Investor's Business Daily)
09:00AM
Jul-26-23 06:15PM
Jul-19-23 12:00PM
Jul-10-23 10:52AM
08:01AM
Jul-06-23 06:15PM
Jul-05-23 08:09AM
Jul-03-23 01:29PM
08:00AM
Jun-29-23 06:15PM
Jun-23-23 06:15PM
Jun-22-23 11:30AM
08:00AM
Jun-14-23 11:54AM
Jun-13-23 12:02PM
Jun-12-23 08:00AM
Jun-08-23 08:00AM
08:00AM
May-26-23 03:56PM
May-24-23 04:16PM
04:11PM
04:00PM
01:17PM
01:01PM
12:55PM
12:55PM
11:15AM
10:34AM
09:00AM
06:56AM
(Thomson Reuters StreetEvents)
04:07AM
May-23-23 07:48PM
05:25PM
04:05PM
03:38PM
May-22-23 06:00PM
May-21-23 03:00PM
May-19-23 11:08AM
08:46AM
08:30AM
May-18-23 09:25PM
12:14PM
09:39AM
08:32AM
07:24AM
May-17-23 03:57PM
07:16AM
May-16-23 06:00PM
02:47PM
11:52AM
11:35AM
10:00AM
09:00AM
08:25AM
07:22AM
May-15-23 01:17PM
12:58PM
12:34PM
08:52AM
07:24AM
May-12-23 02:05PM
02:04PM
Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Gonsalves Rodney V.P., Corporate Controller Aug 23 Sale 118.78 3,500 415,716 24,219 Aug 25 12:53 PM McMullen Michael R. CEO and President Jul 27 Option Exercise 42.12 944 39,761 261,813 Jul 31 03:03 PM McMullen Michael R. CEO and President Jul 27 Sale 130.00 944 122,720 260,869 Jul 31 03:03 PM Ancher-Jensen Henrik Sr Vice President Dec 14 Sale 155.78 29,500 4,595,510 70,793 Dec 15 12:22 PM Grau Dominique Senior Vice President Dec 13 Sale 159.20 4,000 636,800 92,379 Dec 15 12:20 PM MCDONNELL PADRAIG Sr. Vice President Dec 13 Sale 160.00 672 107,520 15,529 Dec 15 12:21 PM KOH BOON HWEE Director Dec 06 Sale 152.21 13,000 1,978,692 57,752 Dec 08 11:31 AM Thaysen Jacob Sr. Vice President Dec 01 Sale 155.65 3,235 503,528 84,464 Dec 02 01:45 PM Thaysen Jacob Sr. Vice President Nov 30 Sale 154.63 9,700 1,499,912 87,699 Dec 02 01:45 PM Gonsalves Rodney V.P., Corporate Controller Nov 23 Sale 156.20 4,634 723,831 28,447 Nov 28 03:47 PM FIELDS HEIDI Director Nov 23 Sale 155.84 3,635 566,482 54,484 Nov 28 03:47 PM McMullen Michael R. CEO and President Nov 22 Option Exercise 40.80 128,726 5,252,021 389,417 Nov 23 01:53 PM McMullen Michael R. CEO and President Nov 22 Sale 155.73 128,726 20,046,500 260,691 Nov 23 01:53 PM Tang Michael SVP, General Counsel, and Sec. Nov 22 Sale 153.90 7,545 1,161,176 46,499 Nov 23 01:54 PM MCDONNELL PADRAIG Sr. Vice President Nov 22 Sale 153.21 2,746 420,715 16,201 Nov 23 01:51 PM McMullen Michael R. CEO and President Nov 16 Option Exercise 40.80 6,775 276,420 277,671 Nov 18 03:03 PM McMullen Michael R. CEO and President Nov 16 Sale 148.19 6,775 1,003,987 270,896 Nov 18 03:03 PM McMullen Michael R. CEO and President Nov 09 Option Exercise 40.80 6,775 276,420 198,133 Nov 10 03:41 PM McMullen Michael R. CEO and President Nov 09 Sale 138.31 6,775 937,050 191,358 Nov 10 03:41 PM McMullen Michael R. CEO and President Nov 02 Option Exercise 40.80 6,775 276,420 198,133 Nov 04 10:54 AM McMullen Michael R. CEO and President Nov 02 Sale 140.61 6,775 952,633 191,358 Nov 04 10:54 AM Tang Michael SVP, General Counsel, and Sec. Nov 01 Sale 139.50 3,600 502,200 43,280 Nov 03 09:52 AM McMullen Michael R. CEO and President Oct 26 Option Exercise 40.80 6,775 276,420 198,133 Oct 27 04:28 PM McMullen Michael R. CEO and President Oct 26 Sale 134.43 6,775 910,763 191,358 Oct 27 04:28 PM McMullen Michael R. CEO and President Oct 19 Option Exercise 40.80 6,775 276,420 198,133 Oct 21 05:01 PM McMullen Michael R. CEO and President Oct 19 Sale 130.11 6,775 881,495 191,358 Oct 21 05:01 PM MCDONNELL PADRAIG Sr. Vice President Sep 28 Sale 122.89 2,103 258,438 13,217 Sep 30 10:34 AM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite